CLBS Key Statistics, Chart & Performance
The current stock price of CLBS is 0.4264 USD. In the past month the price decreased by -21.05%. In the past year, price decreased by -64.47%.
CLBS Latest News, Press Relases and Analysis
CLBS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 25 | 417.40B | ||
| AMGN | AMGEN INC | 15.43 | 181.72B | ||
| GILD | GILEAD SCIENCES INC | 15.46 | 157.14B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.58 | 109.42B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.79 | 80.12B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 855.65 | 57.20B | ||
| INSM | INSMED INC | N/A | 42.01B | ||
| NTRA | NATERA INC | N/A | 31.65B | ||
| BIIB | BIOGEN INC | 10.47 | 25.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.99 | 21.48B | ||
| INCY | INCYTE CORP | 15.9 | 19.93B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.10B |
Related stock screener links
About CLBS
Company Profile
Caladrius Biosciences, Inc. is a biopharmaceutical company, which engages in development of cell therapies for select cardiovascular and autoimmune diseases. The company is headquartered in Basking Ridge, New Jersey and currently employs 27 full-time employees. The firm is developing therapeutics based on the characteristics of naturally occurring CD34+ cells and their ability to stimulate the growth of new microvasculature. The Company’s product candidates include CLBS16, CLBS12 and CLBS201. The CLBS16 (XOWNA) is an experimental regenerative medicine that is being studied in a Phase IIb study (the FREEDOM trial) in the United States for the treatment of coronary microvascular dysfunction. The CLBS12 (HONEDRA) is an experimental regenerative medicine being studied in Japan for the prevention of serious adverse consequences of critical limb ischemia. The CLBS201 is an experimental regenerative medicine designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for diabetic kidney disease.
Company Info
CALADRIUS BIOSCIENCES INC
110 Allen Road, Second Floor
Basking Ridge NEW JERSEY 07920 US
CEO: David J. Mazzo
Employees: 27
Phone: 19082292590.0
CALADRIUS BIOSCIENCES INC / CLBS FAQ
Can you describe the business of CALADRIUS BIOSCIENCES INC?
Caladrius Biosciences, Inc. is a biopharmaceutical company, which engages in development of cell therapies for select cardiovascular and autoimmune diseases. The company is headquartered in Basking Ridge, New Jersey and currently employs 27 full-time employees. The firm is developing therapeutics based on the characteristics of naturally occurring CD34+ cells and their ability to stimulate the growth of new microvasculature. The Company’s product candidates include CLBS16, CLBS12 and CLBS201. The CLBS16 (XOWNA) is an experimental regenerative medicine that is being studied in a Phase IIb study (the FREEDOM trial) in the United States for the treatment of coronary microvascular dysfunction. The CLBS12 (HONEDRA) is an experimental regenerative medicine being studied in Japan for the prevention of serious adverse consequences of critical limb ischemia. The CLBS201 is an experimental regenerative medicine designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for diabetic kidney disease.
What is the current price of CLBS stock?
The current stock price of CLBS is 0.4264 USD. The price decreased by -16.44% in the last trading session.
What is the dividend status of CALADRIUS BIOSCIENCES INC?
CLBS does not pay a dividend.
What is the ChartMill technical and fundamental rating of CLBS stock?
CLBS has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the market capitalization of CLBS stock?
CALADRIUS BIOSCIENCES INC (CLBS) has a market capitalization of 1.72M USD. This makes CLBS a Nano Cap stock.
Can you provide the upcoming earnings date for CALADRIUS BIOSCIENCES INC?
CALADRIUS BIOSCIENCES INC (CLBS) will report earnings on 2022-11-02.
Can you provide the ownership details for CLBS stock?
You can find the ownership structure of CALADRIUS BIOSCIENCES INC (CLBS) on the Ownership tab.
CLBS Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to CLBS. When comparing the yearly performance of all stocks, CLBS is a bad performer in the overall market: 84.2% of all stocks are doing better.
CLBS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CLBS. CLBS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
CLBS Financial Highlights
Over the last trailing twelve months CLBS reported a non-GAAP Earnings per Share(EPS) of -0.41. The EPS increased by 52.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -28.61% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
CLBS Forecast & Estimates
8 analysts have analysed CLBS and the average price target is 4.59 USD. This implies a price increase of 976.45% is expected in the next year compared to the current price of 0.4264.